Mabwell Biotechnology
http://www.maiweibio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mabwell Biotechnology
Corbus Keeps Rising On ADC And Obesity Plans
The company is on a roll thanks to its challenge to Pfizer’s Padcev and competition with a potential obesity market gamechanger from Novo Nordisk.
Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive
The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.
Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.
Mabwell’s Denosumab Biosimilar Shows Similar Efficacy To Xgeva
Mabwell’s denosumab biosimilar MW032, which awaits approval in China, achieved similar efficacy and safety profiles as the originator Xgeva in oncology patients.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Miscellaneous
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Jiangsu T-mab BioPharma Co., Ltd.
- Maiwei (Shanghai) Biotechnology, Mabwell (Shanghai) Bioscience Co. Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice